Triamcinolone ( DrugBank: Triamcinolone )

---

11 diseases

ID	Disease name (Link within this page)	Number of trials
35	Pemphigus	1
46	Malignant rheumatoid arthritis	6
53	Sjogren syndrome	1
56	Behcet disease	2
70	Spinal stenosis	1
90	Retinitis pigmentosa	1
96	Crohn disease	1
107	Juvenile idiopathic arthritis	2
162	Pemphigoid	1
226	Interstitial cystitis with Hunners ulcer	2
298	Hereditary pancreatitis	2

35. Pemphigus

---

Clinical trials : 99 /  Drugs : 124 - (DrugBank : 36) / Drug target genes : 23 - Drug target pathways : 169

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02828163 (ClinicalTrials.gov)	January 2016	27/6/2016	Comparison Between Injections of Steroids and Autologous Platelet Rich Plasma in the Oral Erosions of Pemphigus Vulgaris	Comparative Study Between Intralesional Autologous Platelet Rich Plasma and Intralesional Triamcinolone Acetonide in the Oral Erosions of Pemphigus Vulgaris Patients	Oral Pemphigus Vulgaris	Other: Autologous Platelet rich plasma;Drug: Triamcinolone Acetonide	Cairo University	NULL	Completed	N/A	N/A	All	11	Phase 3	Egypt

46. Malignant rheumatoid arthritis

---

Clinical trials : 4,356 /  Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04361513 (ClinicalTrials.gov)	April 15, 2020	22/4/2020	Genicular Nerve Block in Rheuamtoid Arthritis	Genicular Nerve Block in Rheumatoid Arthritis: a Prospective Randomized Clinical Trial	Pain;Joint Function Disorder;Inflammation	Drug: Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer);Drug: triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip)	Sohag University	NULL	Completed	18 Years	N/A	All	64	Phase 4	Egypt
2	NCT02451748 (ClinicalTrials.gov)	August 2015	6/5/2015	IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA	IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells, Peripheral Blood Monocytes or Differentiated Macrophages of Rheumatoid Arthritis Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA	Rheumatoid Arthritis	Other: Lab Work;Drug: Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg);Drug: Certolizumab pegol (CDP870, tradename Cimzia);Drug: Hydroxychloroquine;Drug: Sulfasalazine;Drug: Medrol;Drug: Prednisone;Drug: Triamcinolone;Drug: Naproxen;Drug: Leflunomide;Drug: Methotrexate;Drug: humira	University of Illinois at Chicago	UCB Pharma	Completed	18 Years	N/A	All	32	Phase 4	United States
3	EUCTR2014-000993-20-SE (EUCTR)	04/12/2014	02/09/2014	Dosing of glucocorticoid (triamcinolone hexacetonid) when injecting knee joints of rheumatic diseases	Dosing of intraarticular triamcinolone hexacetonid for knee synovitis in chronic polyarthritis	Psoriatic arthritis and rheumatoid arthritis with synovitis of the knee;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: triamcinolone hexacetonide (Lederspan) Product Name: triamcinolone hexacetonid (Lederspan) Product Code: 9512 Trade Name: triamcinolone hexacetonide (Lederspan) Product Name: triamcinolone hexacetonid (Lederspan) Product Code: 9512	Center for Research and Development Uppsala University/County Council of Gävleborg	NULL	Not Recruiting			Female: yes Male: yes	160	Phase 4	Sweden
4	NCT01851278 (ClinicalTrials.gov)	April 2013	12/4/2013	Effectiveness Intraarticular Corticosteroid	Effectiveness and Tolerance Infiltration Intraarticular Corticosteroid According to Dose	Rheumatoid Arthritis	Drug: Triamcinolone hexacetonide	Federal University of São Paulo	Fundação de Amparo à Pesquisa do Estado de São Paulo	Recruiting	18 Years	65 Years	Both	60	N/A	Brazil
5	EUCTR2007-006729-28-GB (EUCTR)	25/01/2008	04/12/2007	Is a single dose intramuscular (IM) triamcinolone acetonide injection more effective in treating symptomatic flare in established rheumatoid arthritis than equivalent dose of oral prednisolone? - Treatment comparison for symptomatic flare in RA	Is a single dose intramuscular (IM) triamcinolone acetonide injection more effective in treating symptomatic flare in established rheumatoid arthritis than equivalent dose of oral prednisolone? - Treatment comparison for symptomatic flare in RA	The objective of this study is to compare the efficacy of equivalent doses of IM triamcinolone acetonide and oral prednisolone in controlling a symptomatic flare in patients with established RA. MedDRA version: 9.1;Level: LLT;Classification code 10060732;Term: Rheumatoid arthritis flare up	Trade Name: Kenalog Product Name: Triamcinolone acetonide INN or Proposed INN: TRIAMCINOLONE ACETONIDE Trade Name: Prednisolone Product Name: Prednisolone INN or Proposed INN: PREDNISOLONE	Trafford NHS Trust	NULL	Not Recruiting			Female: yes Male: yes	58		United Kingdom
6	EUCTR2006-005391-40-IT (EUCTR)	25/09/2006	05/06/2007	Study on the effect of intra-articular infiltrations of aulogous platelet gel as inhibitor of erosion in rheumatoid arthritis patients - ND	Study on the effect of intra-articular infiltrations of aulogous platelet gel as inhibitor of erosion in rheumatoid arthritis patients - ND	Patients with Rheumatoid Arthritis Level: PTClassification code 10039073	Product Name: Platelet Rich Plasma INN or Proposed INN: Triamcinolone	AZIENDA OSPEDALIERA SENESE	NULL	Not Recruiting			Female: yes Male: yes			Italy

Back to top

53. Sjogren syndrome

---

Clinical trials : 305 /  Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2100052314	2021-11-01	2021-10-24	Effect of triamcinolone acetonide for parotid gland lavage on the salivary secretion of patients with Sjogren's syndrome	Effect of triamcinolone acetonide irrigation through parotid duct for parotid gland salivary secretion of patients with Sjogren's syndrome	Sjogren syndrome	Experimental Group:Perfusing parotid gland with triamcinolone acetonide injection through parotid duct;Control Group:The parotid gland was perfused with normal saline through parotid duct;	Affiliated Stomatological Hospital of Nanjing Medical University	NULL	Pending	20	80	Both	Experimental Group:27;Control Group:27;	Phase 4	China

56. Behcet disease

---

Clinical trials : 81 /  Drugs : 107 - (DrugBank : 30) / Drug target genes : 36 - Drug target pathways : 116

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2100044593	2021-03-15	2021-03-24	Clinical study of endoscopic treatment for Patients with intestinal Behcet's disease having poor response to conventional treatment	Clinical study of endoscopic treatment for Patients with intestinal Behcet's disease having poor response to conventional treatment	intestinal Behcet's disease	Single group:Endoscopic injection of triamcinolone acetonide;	The First Affiliated Hospital of Sun Yat-Sen University	,NULL	Recruiting	16	70	Both	Single group:30;		China
2	NCT03771768 (ClinicalTrials.gov)	May 25, 2019	1/12/2018	Diode Laser Versus Topical Corticosteroids in Management of Oral Ulcers in Behcet's Disease	Active Control,Randomized,Double- Blinded Clinical Trial of BD	Autoimmune;Behcet Syndrome	Radiation: Diode laser 980nm&100 mWatt;Drug: Triamcinolone Acetonide	Cairo University	NULL	Not yet recruiting	18 Years	60 Years	All	38	N/A	NULL

70. Spinal stenosis

---

Clinical trials : 95 /  Drugs : 169 - (DrugBank : 61) / Drug target genes : 68 - Drug target pathways : 90

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02939482 (ClinicalTrials.gov)	October 1, 2016	15/10/2016	A Study Comparison of Clinical Outcome After Different Rate of Infusion in Caudal Epidural Steroid Injection	A Prospective Study Comparison of Clinical Outcome After Different Rate Infusion in Caudal Epidural Steroid Injection	Spinal Stenosis;Lumbosacral Spondylosis;Radiculopathy	Drug: Triamcinolone Acetonide and normal saline solution	Navamindradhiraj University	NULL	Completed	20 Years	N/A	All	112	N/A	Thailand

90. Retinitis pigmentosa

---

Clinical trials : 147 /  Drugs : 176 - (DrugBank : 43) / Drug target genes : 49 - Drug target pathways : 110

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000022686	2016/07/01	01/07/2016	The Clinical Efficacy of Carbonic Anhydrase Inhibitors and Steroids in the Management of Cystoid Macular Edema in Patients with Retinitis Pigmentosa	The Clinical Efficacy of Carbonic Anhydrase Inhibitors and Steroids in the Management of Cystoid Macular Edema in Patients with Retinitis Pigmentosa - The Clinical Efficacy in the Management of Cystoid Macular Edema in Patients with Retinitis Pigmentosa	retinitis pigmentosa	1% dorzolamide eye drop three times daily in each eye 0.1% betamethasone sodium phosphate eye drop three times daily in each eye oral 250mg acetazolamide two tablets daily 40mg triamcinolone acetonide into the sub-Tenon capsule	Kyushu University Hospital	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	40	Not applicable	Japan

96. Crohn disease

---

Clinical trials : 2,442 /  Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-005455-42-NL (EUCTR)	26/02/2009	18/09/2008	ENDO ACE TRIALEndoscopic Balloon Dilatation of stenotic ileocecal anastomosis in Crohn´s disease with or without additive local steroid injection and oral Budenofalk;a randomized controlled trial - ENDO ACE TRIAL	ENDO ACE TRIALEndoscopic Balloon Dilatation of stenotic ileocecal anastomosis in Crohn´s disease with or without additive local steroid injection and oral Budenofalk;a randomized controlled trial - ENDO ACE TRIAL	Crohn's disease.Patients with Crohn's disease with status after ileocecal resection. Stenotic ileocecal anastomosis with symptoms of obstruction. MedDRA version: 14.1;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders	Trade Name: Budenofalk Product Name: Budenofalk INN or Proposed INN: BUDESONIDE Trade Name: Kenacort Product Name: Kenacort INN or Proposed INN: TRIAMCINOLONE	University Medical Center Utrecht	NULL	Not Recruiting			Female: yes Male: yes	42		Netherlands

107. Juvenile idiopathic arthritis

---

Clinical trials : 447 /  Drugs : 297 - (DrugBank : 57) / Drug target genes : 52 - Drug target pathways : 146

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04614311 (ClinicalTrials.gov)	December 1, 2020	28/10/2020	Strategies Towards Personalised Treatment in Juvenile Idiopathic Arthritis (JIA).	Strategies Towards Personalised Treatment in Juvenile Idiopathic Arthritis (JIA): The MyJIA Trial.	Juvenile Idiopathic Arthritis	Drug: Triamcinolone Hexacetonide 20 MG/ML	Oslo University Hospital	The Research Council of Norway;Haukeland University Hospital;St. Olavs Hospital;University Hospital of North Norway;Helse Stavanger HF	Recruiting	1 Year	18 Years	All	202	Phase 4	Norway
2	EUCTR2019-000889-38-NO (EUCTR)	16/09/2020	18/06/2020	Personalised treatment of my juvenile arthritis	Strategies towards personalised treatment in Juvenile Idiopathic Arthritis (JIA): An open randomised multicentre blinded-assessor trial assessing the effectiveness of intra-articular glucocorticoid injections in JIA patients starting tumour necrosis factor inhibitor treatment - MyJIA	Juvenile idiopathic arthritis is characterised by inflamed joints and is the most common chronic rheumatic disease in childhood and adolescence that potentially lead to disability due to joint damage. A prerequisite for the JIA diagnosis is the detection of inflammation of one or more joints (arthritis). Arthritis leads to pain, swelling and stiffness of the affected joints, caused by hypertrophy of the synovial lining of the joint and increased synovial fluid. Untreated, disability may follow.;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Lederspan INN or Proposed INN: TRIAMCINOLONE HEXACETONIDE	Oslo University Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	202	Phase 4	Norway

162. Pemphigoid

---

Clinical trials : 90 /  Drugs : 122 - (DrugBank : 47) / Drug target genes : 34 - Drug target pathways : 144

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04744623 (ClinicalTrials.gov)	September 30, 2020	2/2/2021	Clinical Evaluation of New Treatment Strategy of Mucous Membrane Pemphigoid Using Large Dose of Prednisolone Plus Intra-lesional of Triamcinolone Acetonide Followed by Combination of Mycophenolate Mofetil, Dapsone and Low Dose Prednisolone	Clinical Evaluation of New Treatment Strategy of Mucous Membrane Pemphigoid Using Large Dose of Prednisolone Plus Intra-lesional of Triamcinolone Acetonide Followed by Combination of Mycophenolate Mofetil, Dapsone and Low Dose Prednisolone	Benign Mucous Membrane Pemphigoid	Drug: large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP	Tanta University	NULL	Active, not recruiting	40 Years	60 Years	All	10	Phase 2/Phase 3	Egypt

226. Interstitial cystitis with Hunners ulcer

---

Clinical trials : 145 /  Drugs : 156 - (DrugBank : 51) / Drug target genes : 64 - Drug target pathways : 146

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03463915 (ClinicalTrials.gov)	January 25, 2019	28/2/2018	Clinical Trial Comparing Two Bladder Instillations for IC/BPS	Randomized Controlled Trial Comparing Two Different Bladder Instillation Treatments for Interstitial Cystitis/Bladder Pain Syndrome	Interstitial Cystitis;Bladder Pain Syndrome	Drug: Bladder instillation WITH triamcinolone acetonide;Drug: Bladder instillation WITHOUT triamcinolone acetonide	Olivia Cardenas-Trowers, M.D.	NULL	Completed	18 Years	N/A	Female	90	Phase 3	United States
2	NCT05223244 (ClinicalTrials.gov)	October 1, 2011	24/1/2022	Bladder Capacity as Objective Measure of Intravesical Treatment of Newly Diagnosed IC	Bladder Capacity as an Objective Measure of Response to Intravesical Treatment of Newly Diagnosed Interstitial Cystitis: a Prospective, Randomized Trial	Interstitial Cystitis;Painful Bladder Syndrome	Drug: bupivacaine, triamcinolone, and heparin (BTH);Drug: dimethyl sulfoxide (DMSO)	NorthShore University HealthSystem	NULL	Completed	18 Years	N/A	Female	83	Phase 4	NULL

298. Hereditary pancreatitis

---

Clinical trials : 95 /  Drugs : 148 - (DrugBank : 51) / Drug target genes : 53 - Drug target pathways : 142

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00658736 (ClinicalTrials.gov)	March 2008	9/4/2008	Efficacy of EUS-guided Celiac Plexus Blockade in Chronic Pancreatitis	A Randomized, Triple-Blinded Study of Endoscopic Ultrasound Guided Celiac Plexus Blockade (EUS-CPB) With Bupivicaine and Triamcinolone vs. Bupivicaine Alone for the Treatment of Pain in Chronic Pancreatitis	Chronic Pancreatitis	Drug: Triamcinolone;Drug: Bupivicaine alone	The Cleveland Clinic	American Society for Gastrointestinal Endoscopy;TAP Pharmaceutical Products Inc.	Completed	18 Years	N/A	All	40	Phase 3	United States
2	NCT00583271 (ClinicalTrials.gov)	June 2002	20/12/2007	A Prospective Study of EUS Guided Celiac Block	A Prospective Study of Endoscopic Ultrasound-guided Celiac (CB) Effectiveness	Chronic Pancreatitis;Pancreatic Cancer	Drug: triamcinolone;Drug: 98% dehydrated alcohol	Indiana University	NULL	Completed	18 Years	N/A	Both	127	N/A	United States

Back to top